BAVENCIO is a programmed death ligand-1 (PD-L1) blocking antibody indicated for: BAVENCIO (avelumab) injection, for intravenous use Initial U.S. Approval: 2017 Bavencio (avelumab) is a medication used for the treatment of metastatic Merkel cell carcinoma (MCC), locally advanced or metastatic urothelial carcinoma, and renal cell carcinoma (RCC).<\/p>\n Disease Indications-Urothelial Carcinoma, Kidney Cancer, Skin Cancer If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication. Our professional will provide you with a step-by-step guide on how to legally and safely import \u201cavelumab injection\u201d based on the information you provide.<\/strong><\/p>\n
\nMerkel Cell Carcinoma (MCC)<\/strong>
\n\u2022 Adults and pediatric patients 12 years and older with metastatic MCC. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be
\ncontingent upon verification and description of clinical benefit in confirmatory trials.
\nUrothelial Carcinoma (UC)<\/strong>
\n\u2022 Maintenance treatment of patients with locally advanced or metastatic UC that has not progressed with first-line platinum-containing chemotherapy.
\n\u2022 Patients with locally advanced or metastatic UC who:
\n\u2022 Have disease progression during or following platinum-containing chemotherapy.
\n\u2022 Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
\nRenal Cell Carcinoma (RCC)<\/strong>
\n\u2022 First-line treatment, in combination with axitinib, of patients with advanced RCC.<\/p>\nHow To access avelumab injection?<\/h3>\n
\nTo access avelumab injection sold under the brand name can be made available on request to patient if the drug has not been approved or is not available in your country. For information or advice, call IPN’s Pharmaceutical Expert. Our expert will be happy to take your query and guide with an effective solution. Be free and call today for full support at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj)<\/p>\n","protected":false},"excerpt":{"rendered":"avelumab injection
\nfor intravenous use Initial U.S. Approval: 2017<\/h2>\nFacts about avelumab injection<\/h4>\n
\nManufacturer-Merck Serono Europe Limited
\nUsage-Intravenous
\nMedicine Approved By-European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Pharmaceuticals and Medical Devices Agency (PMDA), Therapeutic Goods Administration (TGA)
\nSummary of FDA-approved use on approval date: Click Here<\/a>
\n(see Drugs@FDA for complete indication)<\/p>\nAccess the best support services globally<\/h4>\n